Virtuoso Therapeutics
Focus: Virtuoso Therapeutics is a public-stage biotech company headquartered in San Mateo, CA, specializing in therapeutic antibodies for oncology indications. The company maintains an early-stage pipeline focused on solid tumor treatment.
Profile data last refreshed 11h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Virtuoso Therapeutics?
AI assessmentEarly-stage oncology play with public-company infrastructure, but thin pipeline and minimal hiring suggest limited near-term career momentum.
Why Work Here
- Public company status provides liquidity and career stability relative to private biotech peers
- Focused oncology pipeline with VP301 in Phase 1 for solid tumors offers exposure to high-impact therapeutic area
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
The study is to evaluate the use of the Virtuoso Endoscopy System to perform safe and effective bladder lesion excisions.
Bladder NeoplasmClinical Trials (1)
NCT06940648Virtuoso Improving Anatomic Bladder Lesion Excision (VIABLE) Trial
N/AHelp build intelligence for Virtuoso Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.